A Phase 2 interventional study of BXCL501 and BXCL501 in Agitation and Dementia, sponsored by BioXcel Therapeutics Inc. Terminated at 3 sites in United States. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-08-11.
Sponsored by BioXcel Therapeutics Inc · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies testing dexmedetomidine in Psychomotor Agitation — 5 open to participants now, 5 under way, 2 of them phase 3. Dexmedetomidine · Psychomotor Agitation.
Among the 32 studies testing dexmedetomidine in Psychomotor Agitation, this one is the 30th largest by enrollment, is one of 5 that started in 2022, is one of 6 in phase 2, and was the 22nd registered.
231 studies on the registry are indexed under Psychomotor Agitation; 28 are open to participants now.
Browse Psychomotor Agitation studies →5 of the 32 studies testing dexmedetomidine in Psychomotor Agitation are open now, in 3 countries. Recruiting first, the newest first:
Lone Baandrup · Sites in Denmark
Ages 18–64
Temple University · Sites in United States
Ages 18–55
The First Affiliated Hospital with Nanjing Medical University · Sites in China
Ages 18–80
Benha University
Ages 18+
Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal
Ages 18+
By country, each count listing its studies:
Dexmedetomidine: first FDA approval 1999 (PRECEDEX), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 20 Psychomotor Agitation studies recruiting now, 8 (40%) set no upper age limit and 7 (35%) stop at 75 or younger; 4 take children under 18; 2 take healthy volunteers.
This study: 65 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 10 · Phase 3 10 · Phase 4 11
First in 2005; this study’s year is marked. 5 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 5 is below the median of 100 across 188 interventional studies indexed under Psychomotor Agitation.
Median enrollment 73 across the 32 interventional studies. Of the 21 that completed or were terminated, 12 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 32 have an industry lead sponsor. The 10 most frequent:
BioXcel Therapeutics Inc is the lead sponsor of 15 studies on the registry; 1 is open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 9 (75%) have results posted.
11 studies in Psychomotor Agitation by BioXcel Therapeutics Inc: none open now, none under way, none of them phase 3. Of 10 finished, 7 (70%) have results posted.
Among the 11 studies in Psychomotor Agitation by BioXcel Therapeutics Inc, this one is the 10th largest by enrollment, is one of 4 that started in 2022, is one of 3 in phase 2, and was the 6th registered.
BioXcel Therapeutics Inc’s Psychomotor Agitation studies by the year they started, since 2019.
None of the studies under way reaches primary completion within a year.
Among the 32 studies testing dexmedetomidine in Psychomotor Agitation, from their registry updates:
Among BioXcel Therapeutics Inc’s 11 in Psychomotor Agitation:
This tab as a report to print or save as PDF → With an account.
A randomized, double-blind, placebo-controlled parallel group 3-arm study assessing efficacy, safety, and tolerability of two doses BXCL501 in male and female geriatric residents (65 years and older) with acute agitation associated with all forms of dementia (i.e., probably Alzheimer's Disease, vascular dementia; mixed; frontotemporal dementia) excluding Parkinson's-Related Dementia and Lewy Body Dementia.
The study will enroll at least 75 subjects to receive a single film consisting of BXCL501 40 μg dose, BXCL501 60 μg dose, or matching placebo film. Subjects must reside in a residential care facility and must require at least moderate assistance with activities of daily living (e.g., bathing, dressing, and toileting). The subject must be able to self-administer the film to participate in the study.
The effects of BXCL 501 on acute agitation will be assessed by the following scales: PEC, PAS, ACES, and CGI-I.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Sublingual film containing 40 micrograms Dexmedetomidine
Drug: BXCL501
Sublingual film containing 60 micrograms Dexmedetomidine
Drug: BXCL501
Sublingual Placebo film
Drug: Placebo film
Change in Positive and Negative Syndrome Scale- Excited Component (PEC) Total Score
The Positive and Negative Syndrome Scale - Excited Component (PEC) comprises 5 items associated with agitation: poor impulse control, tension, hostility, uncooperativeness, and excitement; each scored 1 (minimum) to 7 (maximum). The PEC, the sum of these 5 subscales, thus ranges from 5 (absence of agitation) to 35 (extremely severe).
Time frame: 120 minutes
Change From Baseline for Pittsburgh Agitation Scale
The Pittsburgh Agitation Scale (PAS) assesses agitation for individuals with dementia across four behavior groups: aberrant vocalizations, motor agitation, aggressiveness, and resisting care. Each behavior group is scored ranging from 0 (not present) to 4 (maximally present).
Time frame: 120 minutes
Change From Baseline for Agitation-Calmness Evaluation Scale
The Agitation-Calmness Evaluation Scale (ACES) is a single item measure rating overall agitation and sedation, where 1 indicates marked agitation; 2 - moderate agitation; 3 - mild agitation; 4 - normal behavior; 5 - mild calmness; 6 - moderate calmness; 7 - marked calmness; 8 - deep sleep; and 9 - unarousable
Time frame: 120 minutes
Clinical Global Impression - Improvement
The Clinical Global Impression - Improvement (CGI-I) for agitation in response to treatment measures the current level of agitation relative to the level of agitation prior to administration of study intervention. The CGI-I scores range from 1 to 7 with a score of 1 indicating very much improved, and a score of 7 indicating very much worse.
Time frame: 120 minutes
The study was conducted in United States from 08 February 2022 to 01 April 2022.
| Milestone | BXCL501: 40 Micrograms | BXCL501: 60 Micrograms | Placebo |
|---|---|---|---|
| Started | 2 | 1 | 2 |
| Completed | 2 | 1 | 2 |
| Not completed | 0 | 0 | 0 |
The Positive and Negative Syndrome Scale - Excited Component (PEC) comprises 5 items associated with agitation: poor impulse control, tension, hostility, uncooperativeness, and excitement; each scored 1 (minimum) to 7 (maximum). The PEC, the sum of these 5 subscales, thus ranges from 5 (absence of agitation) to 35 (extremely severe).
No measurements were reported for this outcome.
The Pittsburgh Agitation Scale (PAS) assesses agitation for individuals with dementia across four behavior groups: aberrant vocalizations, motor agitation, aggressiveness, and resisting care. Each behavior group is scored ranging from 0 (not present) to 4 (maximally present).
No measurements were reported for this outcome.
The Agitation-Calmness Evaluation Scale (ACES) is a single item measure rating overall agitation and sedation, where 1 indicates marked agitation; 2 - moderate agitation; 3 - mild agitation; 4 - normal behavior; 5 - mild calmness; 6 - moderate calmness; 7 - marked calmness; 8 - deep sleep; and 9 - unarousable
No measurements were reported for this outcome.
The Clinical Global Impression - Improvement (CGI-I) for agitation in response to treatment measures the current level of agitation relative to the level of agitation prior to administration of study intervention. The CGI-I scores range from 1 to 7 with a score of 1 indicating very much improved, and a score of 7 indicating very much worse.
No measurements were reported for this outcome.
Collected over Day 1 to Day 7. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| BXCL501: 40 Micrograms | 0/2 (0%) | 0/2 (0%) | 1/2 (50%) |
| BXCL501: 60 Micrograms | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) |
| Placebo | 0/2 (0%) | 0/2 (0%) | 0/2 (0%) |
| Event | BXCL501: 40 Micrograms | BXCL501: 60 Micrograms | Placebo |
|---|---|---|---|
| SomnolenceNervous system disorders | 1/2 | 1/1 | 0/2 |
| Urinary tract infectionInfections and infestations | 0/2 | 1/1 | 0/2 |
| BradycardiaCardiac disorders | 0/2 | 1/1 | 0/2 |
| NauseaGastrointestinal disorders | 1/2 | 0/1 | 0/2 |
| Age, Categorical(Participants) | BXCL501: 40 Micrograms | BXCL501: 60 Micrograms | Placebo | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 0 | 0 | 0 | 0 |
| >=65 years | 2 | 1 | 2 | 5 |
| Sex: Female, Male(Participants) | BXCL501: 40 Micrograms | BXCL501: 60 Micrograms | Placebo | Total |
|---|---|---|---|---|
| Female | 1 | 1 | 0 | 2 |
| Male | 1 | 0 | 2 | 3 |
| Ethnicity (NIH/OMB)(Participants) | BXCL501: 40 Micrograms | BXCL501: 60 Micrograms | Placebo | Total |
|---|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 0 | 1 |
| Not Hispanic or Latino | 1 | 1 | 2 | 4 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | BXCL501: 40 Micrograms | BXCL501: 60 Micrograms | Placebo | Total |
|---|---|---|---|---|
| Caucasian | 2 | 1 | 0 | 3 |
| Black or African American | 0 | 0 | 2 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Feb 2022 to primary completion in Apr 2022, 1 month.
Results were first posted in Aug 2023, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dexmedetomidine
BioXcel Therapeutics Inc